Omada Health (OMDA) CFO Steven Cook Sells $117K of Stock

Omada Health CFO Continues Insider Sales

Steven Cook, the chief financial officer of Omada Health, Inc. (NasdaqGS: OMDA), sold 6,800 shares of company stock on June 15, 2026. The transaction was executed at a price of $17.23 per share, bringing the total value of the sale to $117,164. This planned trade added to a busy stretch of insider activity at the virtual care provider during the month of June.

A Closer Look at Recent Insider Activity

The sale by Cook on June 15 fits into a broader pattern of planned transactions by corporate insiders at Omada Health. Cook executed another planned sale on June 24, parting with 2,600 shares at $19.02 apiece for $49,452, followed by a larger sale of 33,000 shares on June 26 at $19.89 each, valued at $656,370. Other executives also trimmed their holdings in June, including Chief Accounting Officer Craig Gracey, who sold 6,894 shares on June 12 at $17.42 per share for $120,093.48, and another 2,083 shares on June 24 at $19.01 for $39,597.83. Chief Executive Officer Sean Duffy joined the selling trend on June 24 by offloading 2,800 shares at $19.01 each, totaling $53,228. Not all insider movement was outward, however, as Adam Stavisky acquired 10,882 shares on June 16.

Stock Valuation and Trading Levels

Shares of Omada Health changed hands at $17.11 recently, holding close to the 200-day moving average of $17.08. The company features a market capitalization of roughly $1.26 billion and a trailing P/E ratio of 30.76, alongside a forward P/E ratio of 37.05. Over the past year, the equity has moved between a 52-week low of $10.28 and a peak of $26.91, while the 50-day moving average sits higher at $22.27.

Analysts Set New Price Targets

Financial institutions remain largely optimistic about the healthcare firm's trajectory. Freedom Capital Markets reiterated a buy rating with a $35.00 price target on October 14, following earlier reiterations at the same target in September. Barclays maintained an overweight rating on September 11 with a lifted target of $27.00, while Needham kept a buy rating and a $28.00 target on the same day. BTIG also reiterated a buy rating and a $35.00 target on September 11. JP Morgan maintained an overweight rating on August 14 while raising its target to $30.00, and Citizens kept a market outperform rating with a target of $32.00. Baird adjusted its neutral rating on August 12, raising its target to $25.00 from $15.00. Across the broader analyst community, the stock holds a consensus buy recommendation backed by a mean price target of $28.41.

Virtual Care Services Provider

Omada Health operates as a virtual care company delivering chronic disease prevention and management programs across the United States. The enterprise offers cardiometabolic solutions targeting prediabetes, diabetes, and hypertension, alongside physical therapy programs for musculoskeletal issues and behavioral health support. Its digital health platform serves employers, health plans, and pharmacy benefit managers through direct sales channels and partnerships.

Outlook and Upcoming Reports

Market participants are turning their attention toward the company's next financial results release, which is scheduled for November 5, 2026. Insider transactions like these are routine portfolio management steps conducted under pre-arranged plans and do not inherently signal a change in the company's underlying operational health.